Reports Q2 revenue $1.27M, consensus $1.91M. “Our recent achievements demonstrate solid execution across all aspects of our business, as we continue to progress internal and partnered programs according to plan,” said Sean McClain, Founder and CEO. “The new results we are sharing today for ABS-101 represent an important step forward, as we continue to advance this potential best-in-class program toward the clinic. And on the partnership front, we are proud to be adding a world-renowned collaborator in Memorial Sloan Kettering to our list of partners, and look forward to working with them on these innovative new oncology programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
- Absci collaborations with Memorial Sloan Kettering Cancer Center
- Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI
- ABSI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Absci management to meet with Truist